Literature DB >> 15220685

Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study.

George K Anagnostopoulos1, Stavros Tsiakos, George Margantinis, Panagiotis Kostopoulos, Dimitrios Arvanitidis.   

Abstract

BACKGROUND: Esomeprazole has higher oral bioavailability and increased antimicrobial activity against Helicobacter pylori than omeprazole. GOALS: To compare 7 days esomeprazole with 7 days of omeprazole based triple therapies for the eradication of H. pylori, and to assess whether the administration of higher dose of esomeprazole leads to improved eradication rates. STUDY: One hundred and fifty-six dyspeptic patients with H. pylori received either: (1) 1-week treatment including esomeprazole 40 mg once daily, amoxicillin 1 g, and clarithromycin 500 mg, both twice daily (EAC1 group, n = 52); (2) 1-week treatment of omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, all administered twice daily (OAC group, n = 52); or (3) 1-week treatment with esomeprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily (EAC2 group, n = 52).
RESULTS: H. pylori was eradicated in 37 of 52 patients in the OAC group (Intension to treat [ITT] 71%), and in 42 patients in the EAC1 group (ITT 81%). High eradication rate was achieved by the EAC2 regimen (ITT; 96%), but more patients reported unwanted effects.
CONCLUSION: Seven days of esomeprazole based triple therapy is a satisfactory eradication regimen for H. pylori infection. Higher doses of esomeprazole have excellent eradication rates, but they may lead to increased side effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220685     DOI: 10.1097/01.mcg.0000129061.54277.c6

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

1.  Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy on H. pylori eradication.

Authors:  Behsood Yadollahi; Seyed Mohammad Valizadeh Toosi; Zohreh Bari; Hafez Fakheri; Iradj Maleki; Tarang Taghvaei; Vahid Hosseini; Arash Kazemi; Hajar Shokri-Afra
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 2.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

Review 3.  Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness.

Authors:  Enzo Ierardi; Giuseppe Losurdo; Rosa Federica La Fortezza; Mariabeatrice Principi; Michele Barone; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2019-09-14       Impact factor: 5.742

4.  Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice.

Authors:  Kuo-Tung Hung; Shih-Cheng Yang; Cheng-Kun Wu; Hsing-Ming Wang; Chih-Chien Yao; Chih-Ming Liang; Wei-Chen Tai; Keng-Liang Wu; Yuan-Hung Kuo; Chen-Hsiang Lee; Seng-Kee Chuah
Journal:  Infect Drug Resist       Date:  2021-03-25       Impact factor: 4.003

5.  Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis.

Authors:  Wenwen Gao; Xiang Zhang; Yanhui Yin; Shuwen Yu; Lu Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

6.  Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.

Authors:  Waheed Asghar; Elliot Pittman; Fakhreddin Jamali
Journal:  Daru       Date:  2015-11-14       Impact factor: 3.117

7.  Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections.

Authors:  Chia-Jung Kuo; Chun-Wei Chen; Puo-Hsien Le; Jun-Te Hsu; Cheng-Yu Lin; Hao-Tsai Cheng; Ming-Yao Su; Chun-Jung Lin; Cheng-Tang Chiu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-05       Impact factor: 4.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.